#### Alteration of plasma von Willebrand factor in the treatment of

2	retinal vein occlusion with cystoid macular edema
3	Short title: Plasma von Willebrand factor in retinal vein occlusion with macular
4	edema
5	Hiromasa Hirai <sup>1</sup> , Mariko Yamashita <sup>2</sup> , Masanori Matsumoto <sup>3</sup> , Takeyuki
6	Nishiyama <sup>1</sup> , Daishi Wada <sup>1</sup> , Naoko Okabe <sup>1</sup> , Yutaro Mizusawa <sup>1</sup> , Hironobu Jimura <sup>1</sup> ,
7	Tetsuo Ueda <sup>1</sup> , Nahoko Ogata <sup>1*</sup>
8	
9	<sup>1</sup> Department of Ophthalmology, Nara Medical University, Kashihara, Japan
10	Phone: +81-744-29-8884 (ext.3433), Fax: +81-744-23-8032
11	Email: hirai-masa@naramed-u.ac.jp (H.H.), k158380@naramed-u.ac.jp (T.N.),
12	d.wada@naramed-u.ac.jp (D.W.), naoko0811@naramed-u.ac.jp (Naoko
13	Okabe), urotauyuwasazumi@naramed-u.ac.jp (Y.M.), j-hiro@naramed-u.ac.jp
14	(H.J.), tueda@naramed-u.ac.jp (U.T.)
15	<sup>2</sup> Department of Ophthalmology, Nara City Hospital, Nara, Japan
16	Phone: +81-742-24-1251, Fax: +81-744-22-2478

Email: marko.yamashita@gmail.com (M.Y.) 

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- <sup>18</sup> <sup>3</sup>Department of Blood Transfusion Medicine, Nara Medical
- 19 University, Kashihara, Japan
- 20 Phone: +81-744-22-3051, Fax: +81-744-29-0771
- 21 E-mail: <u>mmatsumo@naramed-u.ac.jp</u> (M.M.)
- 22
- 23 \*Corresponding author
- 24 E-mail: ogata@naramed-u.ac.jp (Nahoko Ogata)

## 26 Abstract

27	Retinal vein occlusion (RVO) is a major retinal disease accompanied by venous
28	thrombosis. Although several studies have proposed an association between
29	venous thrombosis and von Willebrand factor (VWF), the association between
30	RVO and VWF remains unclear. We aimed to investigate the association
31	between RVO and VWF and the alteration of VWF levels under the anti-
32	vascular endothelial growth factor (VEGF) treatment. We enrolled 55 patients
33	with RVO involved cystoid macular edema. They received intravitreal injection
34	of anti-VEGF drugs, either ranibizumab or aflibercept. We examined the clinical
35	data, measured plasma VWF: antigen (VWF: Ag) and plasma a disintegrin and
36	metalloproteinase with a thrombospondin type 1 motif, member 13
37	(ADAMTS13) activity (ADAMTS13: AC) and analyzed them to identify
38	variabilities during the treatment. At the baseline there was no significant
39	difference between the RVO group and age-matched controls in both VWF: Ag
40	and ADAMTS13: AC levels but ADAMTS13:AC was significantly lower in central
41	RVO (CRVO) than in branch RVO (BRVO) ( <i>P</i> = 0.015). In BRVO, the negative
42	correlation was found between VWF: Ag and central choroidal thickness (CCT)
43	(r = $-0.51$ , <i>P</i> < 0.001). In BRVO after the anti-VEGF treatment, VWF: Ag

44	decreased significantly from 134% at the baseline to 109% at 1 day after ( $P$ =
45	0.002) and to 107% at 1 month after ( $P = 0.030$ ). In contrast, ADAMTS13: AC
46	showed no significant difference during this period. In BRVO at 1 month after
47	treatment, we found a negative correlation between VWF: Ag and CCT (r =
48	-0.47, $P$ = 0.001). Our findings suggest an association between VWF and CCT
49	in patients with BRVO, thus the measurement of VWF may be useful for
50	evaluating the disease activity and prognosis.

## 52 Introduction

53	Von Willebrand factor (VWF), a large glycoprotein synthesized and secreted
54	from vascular endothelial cells, acts as bridging molecule which adheres
55	platelets to the injured vessels and stabilizes coagulation factor VIII [1]. VWF is
56	specifically cleaved by disintegrin and metalloproteinase with a thrombospondin
57	type 1 motif, member 13 (ADAMTS13) [2]. The balance between VWF and
58	ADAMTS13 maintains the hemostaticaly coagulative function of the whole body.
59	The release of VWF is known to increase with endothelial cell damage and
60	elevated plasma VWF levels are usually observed in patients with hypertension
61	and atherosclerosis [3–5]. Karaca et al. reported an association between
62	plasma VWF and the severity of hypertensive retinopathy [6]. In other ocular
63	diseases, elevated plasma VWF antigen (VWF: Ag) has been reported in age-
64	related macular degeneration (AMD), and multimeric VWF has been found in
65	pachychoroid neovasculopathy [7–9].
66	Several studies have also reported that increased plasma VWF levels are
67	associated with thrombotic complications [10–12]. Interestingly, this association
68	includes not only atherothrombotic diseases (such as myocardial infarction or
69	ischemic stroke) but also venous thrombosis. Edvardsen et al. recently

suggested an association between VWF and venous thrombosis, such	as deep
--	---------

71	vein thrombosis and pulmonary embolism [12].
72	Retinal vein occlusion (RVO) is a major retinal disease that causes retinal
73	hemorrhage and severe vision loss [13,14]. Vision loss in RVO is mainly due to
74	cystoid macular edema (CME). RVO is a multifactorial disease with several risk
75	factors, including age, hypertension, arteriosclerosis, diabetes mellitus,
76	dyslipidemia, high blood viscosity, and thrombosis [14,15]. RVO can be
77	classified into two types: branch RVO (BRVO) and central RVO (CRVO). In
78	BRVO, although partial retinal ischemia may occur, blood perfusion throughout
79	the retina is generally maintained [16]. Alternatively, the entire retina can
80	become severely ischemic in CRVO, which leads to severe vision loss and
81	neovascular glaucoma [17]. Usually, CRVO has a worse prognosis than BRVO.
82	In patients with RVO, it is important to understand the retinal circulatory status
83	to control the disease.
84	Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs has
85	been widely used for the treatment of RVO with CME. However, CME often
86	recurs and requires additional injections. The systemic side effects of anti-
87	VEGF vitreous injection remain controversial. Several studies have reported

88 thromboembolic events, including myocardial infarction and ischemic stroke

89 **[18,19]**.

- <sup>90</sup> In addition, anti-VEGF antibodies are known to enter the systemic circulation,
- 91 decrease VEGF levels and affect other cytokines in the plasma [20]. We have
- <sup>92</sup> already demonstrated that VWF: Ag levels were decreased after intravitreal
- 93 aflibercept injection in patients with AMD [8].
- 94 Although RVO is accompanied by venous thrombosis, few clinical studies have
- 95 examined the association between VWF and RVO and these studies have
- <sup>96</sup> reported different results. Thus, the levels of VWF in RVO remain controversial
- 97 [21–23]. Furthermore, no study has investigated whether plasma VWF is
- <sup>98</sup> influenced by anti-VEGF vitreous injection in patients with RVO.
- In this study, we aimed to investigate the involvement of VWF in the
- 100 pathogenesis of RVO and its variability after anti-VEGF injection.
- 101

## 102 Methods

- 103 This prospective study was conducted at Nara Medical University Hospital,
- 104 Kashihara City, Nara Prefecture, Japan, from June 2014 to March 2020. This
- 105 study protocol was approved by the medical research ethics committee of Nara

106	Medical University and followed the Declaration of Helsinki. We confirmed that
107	all methods were performed in accordance with the relevant guidelines and
108	regulations. All patients provided written informed consent for participation in
109	the study. Fifty-five patients diagnosed as RVO with CME who were aged 51 to
110	91 years and age-matched control subjects (patients before cataract surgery)
111	were enrolled in this study. Patients who had severe systemic complications or
112	did not receive anti-VEGF drugs, that is selected other treatments, were
113	excluded.
114	RVO was diagnosed based on ophthalmological findings, slit lamp examination,
115	fundus examination, optical coherence tomography, wide-angle fundus
116	photography, and fluorescein angiography. We also examined best-corrected
117	visual acuity (BCVA, LogMAR unit), central retinal thickness (CRT), and central
118	choroidal thickness (CCT). The pathological classification (BRVO or CRVO)
119	was judged independently by two researchers based on the examinations.
120	All patients received intravitreal injections of anti-VEGF drugs, either
121	ranibizumab (Lucentis; Novartis International AG, Basel, Switzerland) or
122	aflibercept (Eylea; Bayer HealthCare Pharmaceuticals, Berlin, Germany) at a
123	dose of 2.0 mg/0.05 mL. The drugs were selected by the attending physicians.

124 The intravitreal injection was approached 3.5–4.0 mm posterior to the corneal
125 limbus.

- 126 Whole blood was collected by venipuncture of the anterior arm into a tube
- 127 containing 3.8% trisodium citrate (1:9). Blood samples were collected four
- times: before treatment (first visit), 1 day after treatment, 1 week after treatment,
- and 1 month after treatment. All plasma samples were stored at -80°C and
- 130 thawed at 37°C prior to examination.
- 131 We measured plasma VWF: Ag levels using sandwich enzyme-linked
- 132 immunosorbent assay (ELISA), rabbit anti-human VWF polyclonal antiserum
- 133 (DAKO, Glostrup, Denmark) [24], and plasma ADAMTS13 activity (ADAMTS13:
- 134 AC) by chromogenic ADAMTS13 activity ELISA (Kainos, Tokyo, Japan) [25].
- 135 We defined the 100% reference value as the amount of VWF: Ag and
- ADAMTS13: AC in pooled normal plasma from 20 volunteers (10 men and 10
- 137 women) aged between 20 and 40 years.
- 138 All statistical analyses were performed using EZR (Saitama Medical Center,
- 139 Jichi Medical University, Saitama, Japan), a graphical user interface for R (The
- 140 R Foundation for Statistical Computing, Vienna, Austria) [26]. We used t-tests to
- 141 compare two continuous variables (such as age) and Fisher's exact tests to

142	compare the proportions of categorical variables (such as sex) between the
143	groups. We also used the Friedman and Wilcoxon signed-rank tests to compare
144	the four continuous variables (VWF: Ag). Correlations were evaluated using
145	Pearson's correlation coefficient. The threshold for significance was set at $P$ <
146	0.05.

147

## 148 **Results**

The characteristics of the patients with RVO and controls are summarized in 149 150 Table 1. In patients with RVO, the median age was 73.0 years, and 33 (60%) 151 were male. Twenty-seven (49%) patients had hypertension. There was no 152 significant difference in VWF: Ag and ADAMTS13: AC between the RVO group and the controls (P = 0.70 and P = 0.22, respectively). We also examined the 153 154 baseline characteristics of patients with RVO classified according to RVO type, 155 BRVO and CRVO. Both CRT and CCT were significantly thicker in CRVO than in BRVO (P = 0.013 and 0.045, respectively). The number of dyslipidemia 156 157 cases was also significantly higher in CRVO than in BRVO (P = 0.004). 158 Although VWF: Ag showed no significant difference between the two groups (P = 0.18), ADAMTS13:AC was significantly lower in CRVO than in BRVO (P = 159

#### 160 0.015). In other categories, there were no significant differences between the

### 161 two groups.

- 162 We assessed the blood type because the blood O group had lower plasma
- 163 VWF: Ag levels than the other groups [27]. There was no difference in the blood
- 164 type between the two groups.

178

	•					
	Total RVO	Control	Р	BRVO	CRVO	Р
	(n=55)	(n=96)	value	(n=43)	(n=12)	value
Age, median (IQR)	73.0 (65.0-79.0)	74.0 (69.0-80.0)	0.18†	73.0 (66.0-79.5)	72.0 (64.0-74.3)	0.33†
Sex (male), n (%)	33 (60)	52 (54)	0.50‡	23 (53)	10 (83)	0.10‡
BCVA, median (IQR),	0.40 (0.15-0.52)	—		0.30 (0.15-0.52)	0.40 (0.28-0.57)	0.19†
CRT (µm), median (IQR)	477 (357-614)	—		440 (343-586)	574 (491-747)	0.013†
CCT (µm), median (IQR)	238 (197-264)	—		235 (180-259)	257 (214-298)	0.045†
Hypertension, n (%)	27 (49)	—		20 (47)	7 (58)	0.53‡
Dyslipidemia, n (%)	13 (24)	—		6 (14)	7 (58)	0.004‡
Diabetes, n (%)	6 (11)	—		4 (9)	2 (17)	0.60‡
Cardiovascular disease, n (%)	8 (15)	—		6 (14)	2 (17)	1‡
VWF (%), median (IQR)	134 (92-173)	130 (109-167)	0.70†	139 (107-175)	92 (60-122)	0.18†
ADAMTS13 (%), median (IQR)	45 (33-61)	54 (45-63)	0.22†	51 (38-69)	34 (29-39)	0.015†
Blood Type, n (%)						
Туре О	18 (33)	32 (33)	1‡	12 (28)	6 (50)	0.18‡
Туре А	23 (42)	34 (35)	0.49‡	19 (44)	4 (33)	0.74‡
Туре В	9 (16)	16 (17)	1‡	9 (21)	0 (0)	0.18‡
Туре АВ	5 (9)	14 (15)	0.45‡	3 (7)	2 (17)	0.30‡

Table 1: Basic characteristics of RVO patients and control

RVO, retinal vein occlusion

IQR, interquartile range

BRVO, branch retinal vein occlusion

CRVO, central retinal vein occlusion

	BCVA, best-corrected visual acuity (LogMAR unit)
	CRT, central retinal thickness
	CCT, central choroidal thickness
	VWF, Von Willebrand factor
	† t test
	‡ fisher's exact test
180	
181	
182	
183	
184	
185	
186	
187	

188

189	Fia. 1	shows the	correlation	between	VWF: A	Ag and	each	parameter	at the
102	1 19. 1		00110101011	000000000000000000000000000000000000000	* * * 1 . /	ig and	Cuon	purumotor	

- 190 baseline. In BRVO, there was a positive correlation between VWF: Ag and CRT
- 191 (r = 0.30, P = 0.049). We also found a strong negative correlation between
- 192 VWF: Ag and CCT (r = -0.51, P < 0.001). In CRVO, no correlations were found
- in any of the categories.

194

195 Fig. 1. The correlation between VWF: Ag and parameters (BCVA, CRT, and

196 **CCT) at the baseline.** In each graph, the horizontal axis presents the VWF: Ag

197 (%). VWF: Ag, plasma VWF: antigen; BCVA, best-corrected visual acuity

198 (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness.

199

200 Table 2 shows the basic characteristics of patients with RVO classified

according to the selected anti-VEGF drugs. We confirmed that there were no

202 significant differences between the two groups.

203

204

Table 2: Basic characteristics of patients classified by anti-VEGF drugs							
	Aflibercept	Ranibizumab	Р				
	(n=28)	(n=27)	value				
Age, median (IQR)	74.0 (66.0-79.0)	72.0 (63.5-78.0)	0.78†				
Sex (male), n (%)	15 (54)	18 (67)	0.41‡				
RVO type	21 / 7	22 / 5	0.75‡				
(BRVO / CRVO)							
BCVA, median (IQR)	0.22 (0.14-0.52)	0.39 (0.26-0.61)	0.17†				
CRT (µm), (IQR)	456 (358-626)	481 (371-586)	1†				
CCT (µm), (IQR)	233 (199-257)	251 (187-278)	0.58†				
VWF (%), median (IQR)	118 (82-164)	139 (111-183)	0.54†				
ADAMTS13 (%), median (IQR)	40 (31-53)	51 (34-69)	0.67†				
IQR, interquartile range							
BRVO, branch retinal vein occlusion							
CRVO, central retinal vein occlus	ion						
BCVA, best-corrected visual acuity (LogMAR unit)							
CRT, central retinal thickness							
CCT, central choroidal thickness							
VWF, Von Willebrand factor							
† t test ‡ Fisher's exact test							

#### . .. ... -. . . . . . ...

216

Table 3 shows the alterations of clinical data in patients with RVO by treatment.

- In total RVO, BCVA significantly improved from 0.40 at the baseline to 0.22 at 1
- 220 month after anti-VEGF treatment (*P* < 0.001). Both CRT and CCT were
- significantly thinner at 1 month after treatment (*P* < 0.001 and 0.001,
- respectively). In BRVO, BCVA also significantly improved from 0.35 at the
- baseline to 0.15 at 1 month after treatment (*P* < 0.001). Both CRT and CCT
- were significantly thinner at 1 month after treatment (P < 0.001 and P = 0.003,
- respectively). In CRVO, BCVA significantly improved from 0.40 at the baseline
- to 0.35 at 1 month after treatment (*P* = 0.004). CRT was significantly thinner at
- 1 month after treatment (P < 0.001), whereas there was no significant difference
- 228 in CCT (*P* = 0.24).

229

230

	Total RVO		Р	BRVO		Р	CRVO		Р
	(n=55)		value	(n=43)		value	(n=12)		value
	Baseline	1 month		Baseline	1 month		Baseline	1 month	
BCVA, median	0.40	0.22	< 0.001†	0.35	0.15	< 0.001†	0.40	0.35	0.040†
(IQR)	(0.15-0.52)	(0.05-0.40)		(0.15-0.52)	(0.05-0.46)		(0.28-0.57)	(0.21-0.40)	
CRT(µm), median	477	224	< 0.001†	440	222	< 0.001†	574	239	<0.001†
(IQR)	(357-614)	(199-251)		(343-586)	(196-244)		(491-747)	(219-258)	
CCT (µm), median	238	215	0.001†	235	213	0.003†	257	242	0.24†
(IQR)	(197-264)	(174-270)		(180-259)	(160-267)		(214-298)	(204-290)	

 Table 3: Alterations of clinical data in patients with RVO by treatments

IQR, interquartile range

BRVO, branch retinal vein occlusion

CRVO, central retinal vein occlusion

BCVA, best-corrected visual acuity (LogMAR unit)

CRT, central retinal thickness

CCT, central choroidal thickness

† paired t test

232

234	Fig. 2 shows the correlation between VWF: Ag and each parameter 1 month
235	after anti-VEGF treatment. In BRVO, we found a negative correlation between
236	VWF: Ag and CCT (r = $-0.47$ , P = 0.001). In CRVO, no correlations were found
237	in any of the categories.
238	
239	Fig. 2. The correlation between VWF: Ag and parameters (BCVA, CRT, and
240	CCT) 1 month after anti-VEGF treatment. In each graph, the horizontal axis
241	presents the VWF: Ag (%). VWF: Ag, plasma VWF: antigen; BCVA, best-
242	corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT,
243	central choroidal thickness.
244	
245	Fig. 3 shows the time course of VWF: Ag in patients with total RVO, BRVO, and
246	CRVO. In total RVO, VWF: Ag decreased significantly from 134% at the
247	baseline to 104% at 1 day after treatment ( $P = 0.002$ ). In BRVO, VWF: Ag also
248	showed a significant reduction from 139% at baseline to 113% at 1 day after
249	treatment ( $P = 0.002$ ) and to 98% at 1 month after treatment ( $P = 0.030$ ).
250	However, in CRVO, VWF: Ag showed no significant difference during this
251	period. ADAMTS13: AC showed no significant difference during the study

252 period in all categories.

253

### Fig 3. Alterations of VWF: Ag after anti-VEGF treatment (\*< 0.05, \*\*< 0.01).

- Each of the values above the graph presents the median with the interquartile
- 256 range.

## 258 **Discussion**

- 259 This study investigated the coagulation-related factors in patients with RVO at
- the baseline and their alterations during the treatment.
- According to our results, there was no significant difference in plasma VWF
- between the RVO and age-matched controls at the baseline. Several
- <sup>263</sup> researchers have reported that plasma VWF increased not only in patients with
- hypertension and arteriosclerosis but also in healthy individuals with aging
- 265 **[28,29]**.
- ADAMTS13:AC was significantly lower in CRVO than in BRVO at the baseline.
- <sup>267</sup> Interestingly, the number of dyslipidemia cases was significantly higher in
- 268 CRVO than in BRVO. ADAMTS13 is mainly synthesized in hepatic stellate cells
- [269 [2]. Thus the liver cells in patients with dyslipidemia would be damaged by fat
- deposition, then production of ADAMTS13 could be decreased in patients with

271 CRVO.

- 272 Although it was not statistically significant, the VWF levels in BRVO were higher
- than those in CRVO. BRVO is accompanied by a thrombus at the arteriovenous
- crossing point where the retinal artery and vein share an outer sheath [30,31],
- therefore the arterial pressure directly cause thrombosis. Alternatively, CRVO is

276	accompanied by a thrombus in the central retinal vein where it passes through
277	the lamina cribrosa within the optic nerve. A recent study focusing on BRVO
278	and CRVO has shown that atherosclerosis is a more inducing factor for
279	developing BRVO than that for CRVO [32]. High levels of plasma VWF in our
280	study suggest the atherosclerosis in BRVO.
281	We also compared VWF levels and each ophthalmologic parameters of RVO
282	and found a significant negative correlation between VWF: Ag and CCT in
283	BRVO at the baseline. Although studies examining the association between
284	VWF and choroidal thickness are few, Gifford et al. reported an inverse
285	association between choroidal thickness and VWF in patients with liver cirrhosis
286	[33]. Many previous reports demonstrated that choroidal thickness in patients
287	with RVO decreases after intravitreal injection of anti-VEGF drugs [34].
288	Sakanishi et al. reported that the recurrence of CME was significantly few in
289	cases with choroidal thinning after treatment [35]. Thus, CCT may reflect the
290	treatment effect and prognosis in RVO. Interestingly, a significant negative
291	correlation between VWF: Ag and CCT was still observed 1 month after anti-
292	VEGF injection in BRVO. Therefore, the measurement of VWF: Ag during the
293	treatment may be useful in evaluating the disease activity of BRVO. VWF: Ag

294	also showed	significant	alterations	under anti-V	/EGF tre	eatment, e	specially	/ in
						,		

- <sup>295</sup> BRVO. Several researchers have previously proposed the association between
- 296 VWF and VEGF [36,37]. VWF is secreted from endothelial-specific organelles,
- 297 called Weibel palade bodies (WPBs) which widely distribute in the systemic
- vessels [2]. VEGF activates exocytosis of WPBs, resulting in the release of
- 299 VWF [37,38] which activates VEGF-R2 signaling and may promote
- angiogenesis [39]. Although few studies have examined the association
- 301 between anti-VEGF drugs and VWF, Pace et al. reported decreased VWF
- 302 plasma levels after anti-VEGF treatment (bevacizumab) in recurrent glioma [40].
- 303 We also report the VWF reduction after anti-VEGF treatment in patients with
- 304 BRVO. Thus, the alterations of VWF may reflect the therapeutic effect after anti-
- 305 VEGF drug administration in BRVO.
- 306 This study has some limitations. First, this was a cross-sectional study with a
- 307 relatively small sample size. A larger number of patients will be required for
- 308 more accurate analyses. Second, we only assessed patients who received anti-
- 309 VEGF drugs. It might be necessary to compare VWF levels in patients with and
- 310 without treatment at the same time course. However, it is difficult to analyze
- 311 untreated patients through frequent medical visits. Finally, we did not evaluate

- the long-term effects of anti-VEGF drugs for more than 1 month after intravitreal
- injection. A longer follow-up period is required to confirm these results.
- 314

## 315 **Conclusion**

- In summary, we performed prospective analyses on VWF in patients with RVO
- 317 during the treatment and found unique characteristics. Our findings suggest an
- association between VWF and CCT in BRVO, thus the measurement of VWF
- 319 may be useful for evaluating the disease activity and prognosis.
- 320

## 321 Acknowledgements

- 322 The authors thank Hiroki Tsujinaka for his useful discussions and Editage
- 323 (www.editage.com) for English language editing.

324

- 326
- 327
- 328

## 329 **References**

- 1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev
- Biochem. 1998;67: 395-424. doi: <u>10.1146/annurev.biochem.67.1.395</u>, PubMed
- 332 PMID: <u>9759493</u>.
- 2. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the
- 334 scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.
- 335 Blood. 2011;118: 3212-3221. doi: <u>10.1182/blood-2011-02-306597</u>, PubMed
- 336 PMID: <u>21715306</u>, PubMed Central PMCID: <u>PMC3179391</u>.
- 337 3. Blann AD, Naqvi T, Waite M, McCollum CN. Von Willebrand factor and
- endothelial damage in essential hypertension. J Hum Hypertens. 1993;7: 107-
- 339 **111. PubMed PMID:** <u>8510081</u>.
- 4. Blann AD, McCollum CN. Von Willebrand factor, endothelial cell damage and
- 341 atherosclerosis. Eur J Vasc Surg. 1994;8: 10-15. doi: <u>10.1016/s0950-</u>
- 342 <u>821x(05)80112-4</u>, PubMed PMID: <u>8307205</u>.
- 5. Lip GY, Blann A. Von Willebrand factor: a marker of endothelial dysfunction
- in vascular disorders? Cardiovasc Res. 1997;34: 255-265. doi: <u>10.1016/s0008-</u>
- 345 <u>6363(97)00039-4</u>, PubMed PMID: <u>9205537</u>.
- 6. Karaca M, Coban E, Ozdem S, Unal M, Salim O, Yucel O. The association

- 347 between endothelial dysfunction and hypertensive retinopathy in essential
- <sup>348</sup> hypertension. Med Sci Monit. 2014;20: 78-82. Epub: 78–82. doi:
- 349 <u>10.12659/MSM.889659</u>, PubMed PMID: <u>24441931</u>, PubMed Central PMCID:
- 350 <u>PMC3907530</u>.
- 351 **7.** Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular
- degeneration is associated with increased vascular endothelial growth factor,
- hemorheology and endothelial dysfunction. Ophthalmology. 2001;108: 705-710.
- 354 doi: <u>10.1016/s0161-6420(00)00663-1</u>, PubMed PMID: <u>11297487</u>.
- 8. Yamashita M, Matsumoto M, Hayakawa M, Sakai K, Fujimura Y, Ogata N.
- 356 Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates
- <sup>357</sup> plasma von Willebrand factor in patients with age-related macular degeneration.
- 358 Sci Rep.: 2018: 8(1):1491. doi: <u>10.1038/s41598-018-19473-0</u>, PubMed PMID:
- 359 <u>29367644</u>, PubMed Central PMCID: <u>PMC5784081</u>.
- 360 9. Hirai H, Yamashita M, Matsumoto M, Hayakawa M, Sakai K, Ueda T, et al.
- 361 Analysis focusing on plasma von Willebrand factor in pachychoroid
- neovasculopathy and age-related macular degeneration. Sci Rep.: 2021:
- 363 11(1):19987. Epub: 20211007. doi: <u>10.1038/s41598-021-99557-6</u>, PubMed
- 364 PMID: <u>34620972</u>, PubMed Central PMCID: <u>PMC8497477</u>.

365	10. Buchtele N, Sch	wameis M, Gilbert	JC, Schörgenhofer	C, Jilma B. Targeting

- 366 von Willebrand factor in ischaemic stroke: focus on clinical evidence. Thromb
- 367 Haemost. 2018;118: 959-978. doi: <u>10.1055/s-0038-1648251</u>, PubMed PMID:
- 368 29847840, PubMed Central PMCID: PMC6193403 established to discover and
- 369 develop novel biotherapeutics targeting von Willebrand factor. Other authors
- declare no conflict of interest.
- 11. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular
- disease: focus on acute coronary syndromes. Circulation. 2008;117: 1449-
- 373 1459. doi: <u>10.1161/CIRCULATIONAHA.107.722827</u>, PubMed PMID: <u>18347221</u>.
- 12. Edvardsen MS, Hindberg K, Hansen ES, Morelli VM, Ueland T, Aukrust P,
- 375 et al. Plasma levels of von Willebrand factor and future risk of incident venous
- thromboembolism. Blood Adv. 2021;5: 224-232. doi:
- 377 <u>10.1182/bloodadvances.2020003135</u>, PubMed PMID: <u>33570640</u>, PubMed
- 378 Central PMCID: <u>PMC7805310</u>.
- 13. Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the
- 380 classification, pathogenesis, risk factors, natural history, and treatment of
- branch retinal vein occlusion. J Ophthalmol. 2017;2017: 4936924. doi:
- 382 <u>10.1155/2017/4936924</u>, PubMed PMID: <u>28386476</u>, PubMed Central PMCID:

#### 383 PMC5366235.

- 14. Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al.
- 385 Prevalence and systemic risk factors for retinal vein occlusion in a general
- Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2010;51:
- 387 3205-3209. doi: <u>10.1167/iovs.09-4453</u>, PubMed PMID: <u>20071683</u>.
- 388 15. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-
- analysis of published clinical data. J Ophthalmol. 2014;2014. Epub: 724780:
- 390 724780. doi: <u>10.1155/2014/724780</u>, PubMed PMID: <u>25009743</u>, PubMed Central
- 391 PMCID: PMC4070325.
- 16. Hamid S, Mirza SA, Shokh I. Branch retinal vein occlusion. J Ayub Med Coll
- 393 Abbottabad. 2008;20: 128-132. [Epub 2009/04/24]. PubMed PMID: <u>19385476</u>.
- 17. Bradshaw SE, Gala S, Nanavaty M, Shah A, Mwamburi M, Kefalas P.
- 395 Systematic literature review of treatments for management of complications of
- ischemic central retinal vein occlusion. BMC Ophthalmol. 2016;16: 104. Epub:
- 397 104. doi: <u>10.1186/s12886-016-0282-5</u>, PubMed PMID: <u>27401800</u>, PubMed
- 398 Central PMCID: <u>PMC4940864</u>.
- 18. Falavarjani KG, Nguyen QD. Adverse events and complications associated
- 400 with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond).

- 401 2013;27: 787-794. Epub: 787–794. doi: <u>10.1038/eye.2013.107</u>, PubMed PMID:
- 402 <u>23722722</u>, PubMed Central PMCID: <u>PMC3709385</u>.
- 403 19. Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk.
- 404 Intern Emerg Med. 2020;15: 199-210. Epub: 199–210. doi: 10.1007/s11739-
- 405 <u>019-02253-7</u>, PubMed PMID: <u>31848994</u>.
- 406 20. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T.
- 407 Plasma levels of vascular endothelial growth factor and pigment epithelium-
- 408 derived factor before and after intravitreal injection of bevacizumab. Br J
- 409 Ophthalmol. 2010;94(9):1215-8. Epub: 20100610. doi:
- 410 <u>10.1136/bjo.2008.156810</u>, PubMed PMID: <u>20538658</u>.
- 411 21. Cortinovis A, Crippa A, Crippa M. Factor VIII/Ag (von Willebrand) and
- 412 protein C. Erythrocyte deformability and aggregability. The risk parameters of
- 413 retinal vein occlusion. Minerva Med. 1994;85: 211-219. [Epub 1994/05/01].
- 414 PubMed PMID: <u>8028749</u>.
- 415 22. Lip PL, Blann AD, Jones AF, Lip GY. Abnormalities in haemorheological
- factors and lipoprotein (a) in retinal vascular occlusion: implications for
- 417 increased vascular risk. Eye (Lond). 1998;12: 245-251. doi:
- 418 <u>10.1038/eye.1998.58</u>, PubMed PMID: <u>9683948</u>.

- 419 23. Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma
- 420 homocysteine, methylene tetrahydrofolate reductase C677T and factor II
- 421 G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion.
- 422 Br J Ophthalmol. 2001;85: 1313-1315. doi: <u>10.1136/bjo.85.11.1313</u>, PubMed
- 423 PMID: <u>11673296</u>, PubMed Central PMCID: <u>PMC1723784</u>.
- 424 24. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, et al.
- 425 Platelets treated with ticlopidine are less reactive to unusually large von
- 426 Willebrand factor multimers than are those treated with aspirin under high shear
- 427 stress. Pathophysiol Haemost Thromb. 2005;34: 35-40. doi:
- 428 <u>10.1159/000088546</u>, PubMed PMID: <u>16293984</u>.
- 429 25. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel
- 430 monoclonal antibody-based enzyme immunoassay for determining plasma
- 431 levels of ADAMTS13 activity. Transfusion. 2006;46: 1444-1452. doi:
- 432 <u>10.1111/j.1537-2995.2006.00914.x</u>, PubMed PMID: <u>16934083</u>.
- 433 26. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for
- 434 medical statistics. Bone Marrow Transplant. 2013;48: 452-458. doi:
- 435 <u>10.1038/bmt.2012.244</u>, PubMed PMID: <u>23208313</u>, PubMed Central PMCID:
- 436 **PMC3590441**.

- 437 27. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E,
- 438 et al. A shorter von Willebrand factor survival in O blood group subjects explains
- 439 how ABO determinants influence plasma von Willebrand factor. Blood.
- 440 2008;111: 3540-3545. doi: <u>10.1182/blood-2007-11-122945</u>, PubMed PMID:
- 441 <u>18245665</u>.
- 442 28. Alavi P, Rathod AM, Jahroudi N. Age-associated increase in
- thrombogenicity and its correlation with von Willebrand factor. J Clin Med.
- 444 2021;10. Epub: 20210916. doi: <u>10.3390/jcm10184190</u>, PubMed PMID:
- 445 <u>34575297</u>, PubMed Central PMCID: <u>PMC8472522</u>.
- 446 29. Biguzzi E, Castelli F, Lijfering WM, Cannegieter SC, Eikenboom J,
- 447 Rosendaal FR, et al. Rise of levels of von Willebrand factor and factor VIII with
- age: role of genetic and acquired risk factors. Thromb Res. 2021;197: 172-178.
- 449 Epub: 172–178. doi: <u>10.1016/j.thromres.2020.11.016</u>, PubMed PMID:
- 450 <u>33221577</u>.
- 451 **30**. Hawkins WR. Anatomy of arteriovenous crossings in branch retinal vein
- 452 occlusion. Am J Ophthalmol. 1990;110: 97-98. doi: <u>10.1016/s0002-</u>
- 453 <u>9394(14)76953-3</u>, PubMed PMID: <u>2368833</u>.
- 454 31. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D.

- 455 Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol.
- 456 1982;100: 1132-1140. doi: <u>10.1001/archopht.1982.01030040110020</u>, PubMed
- 457 PMID: <u>6178389</u>.
- 458 32. Lyu M, Lee Y, Kim BS, Kim HJ, Hong R, Shin YU, et al. Clinical significance
- 459 of subclinical atherosclerosis in retinal vein occlusion. Sci Rep.: 2021:
- 460 11(1):11905. Epub: 20210607. doi: <u>10.1038/s41598-021-91401-1</u>, PubMed
- 461 PMID: <u>34099806</u>, PubMed Central PMCID: <u>PMC8184809</u>.
- 462 33. Gifford FJ, Moroni F, Farrah TE, Hetherington K, MacGillivray TJ, Hayes
- 463 PC, et al. The eye as a non-invasive window to the microcirculation in liver
- cirrhosis: A prospective pilot study. J Clin Med. 2020;9. Epub: 20201017. doi:
- 465 <u>10.3390/jcm9103332</u>, PubMed PMID: <u>33080821</u>, PubMed Central PMCID:
- 466 <u>PMC7603064</u>.
- 467 34. Kim KH, Lee DH, Lee JJ, Park SW, Byon IS, Lee JE. Regional choroidal
- thickness changes in branch retinal vein occlusion with macular edema.
- 469 Ophthalmologica. 2015;234: 109-118. Epub: 109–118. doi: 10.1159/000437276,
- 470 PubMed PMID: <u>26305536</u>.
- 471 35. Sakanishi Y, Morita S, Mashimo K, Tamaki K, Ebihara N. Subfoveal
- 472 choroidal thickness and treatment outcomes of intravitreal Aflibercept for branch

- 473 retinal vein occlusion. Life (Basel). 2021;11. Epub: 20210617. doi:
- 474 <u>10.3390/life11060572</u>, PubMed PMID: <u>34204557</u>, PubMed Central PMCID:
- 475 **PMC8235093**.
- 476 36. Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ,
- 477 et al. The heparin binding domain of von Willebrand factor binds to growth
- 478 factors and promotes angiogenesis in wound healing. Blood. 2019;133: 2559-
- 479 2569. Epub: 2559–2569. doi: <u>10.1182/blood.2019000510</u>, PubMed PMID:
- 480 <u>30975637</u>, PubMed Central PMCID: <u>PMC6566593</u>.
- 481 37. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and
- 482 plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc
- 483 Biol. 2006;26: 1002-1007. doi: <u>10.1161/01.ATV.0000209501.56852.6c</u>, PubMed
- 484 PMID: <u>16469951</u>.
- 485 38. Randi AM. Endothelial dysfunction in von Willebrand disease: angiogenesis
- and angiodysplasia. Thromb Res. 2016;141;Suppl 2: S55-S58. doi:
- 487 <u>10.1016/S0049-3848(16)30366-8</u>, PubMed PMID: <u>27207426</u>.
- 488 39. Mojzisch A, Brehm MA. The manifold cellular functions of von Willebrand
- 489 factor. Cells. 2021;10. Epub: 20210908. doi: <u>10.3390/cells10092351</u>, PubMed
- 490 PMID: <u>34572000</u>, PubMed Central PMCID: <u>PMC8466076</u>.

- 491 40. Pace A, Mandoj C, Antenucci A, Villani V, Sperduti I, Casini B, et al. A
- 492 predictive value of von Willebrand factor for early response to bevacizumab
- therapy in recurrent glioma. J Neurooncol. 2018;138: 527-535. doi:
- 494 <u>10.1007/s11060-018-2820-x</u>, PubMed PMID: <u>29594657</u>.



Figure



Figure

Total RVO

## BRVO

## CRVO



# Figure